Obtain prior authorization for indicated implant uses

Medical necessity is specified per product and indication; obtain prior authorization consistent with plan processes when requesting implants such as Retisert (0.59 mg) for chronic noninfectious intermediate/posterior/pan uveitis, Iluvien (0.19 mg) for DME after prior corticosteroid without clinically significant IOP rise, Ozurdex (0.7 mg) for uveitis/RVO/DME, or Dextenza (0.4 mg) for postoperative inflammation/pain.

Include indication-specific justification and prior therapy history with PA

PA requests must include indication-specific clinical justification and prior therapy history (including prior anti‑VEGF for DME or systemic steroids/immunosuppression for uveitis), plus lens status and intraocular pressure history because of cataract and IOP risks.

Verify PA for J7311, J7312, J7314 per member benefits

Procedure codes listed in the coding section include J7311, J7312, and J7314; coverage and prior authorization are dependent on medical necessity and member benefit determinations—verify payer PA rules before billing.

Submit J7312/J7313 for policy review (J7313 = covered when medically necessary)

This policy references procedure codes J7312 and J7313; J7313 is explicitly listed as 'Covered when medically necessary' and therefore requires policy-based review and likely PA per payer process.

Confirm PA requirements for J1096 before billing

Code J1096 is listed as 'covered when medically necessary' in the policy; providers should confirm whether prior authorization is required by the member’s plan before submitting claims.

Ensure PA submission uses current policy-aligned codes

Prior authorization requirements are tied to the policy's coding table; the policy history shows codes (e.g., J1096, J7313, J7314, 0356T, 68841) have been added, removed, or reclassified—ensure the codes submitted match the current policy table.

Document prior corticosteroid trial and IOP response for Iluvien PA

Iluvien (fluocinolone acetonide 0.19 mg) is indicated for DME only in patients previously treated with a course of corticosteroids who did not have a clinically significant rise in intraocular pressure, implying documentation of prior corticosteroid exposure is required.

Demonstrate prior anti‑VEGF or intolerance before implant use for DME

Implant therapies for conditions such as DME are considered when other therapies (for example, anti‑VEGF agents) are inadequate or not tolerated; PA may require evidence of inadequate response or intolerance to prior therapies.

Document prior topical therapy (or rationale) for punctum insert PA

Trials of the punctum dexamethasone insert did not clarify whether participants were treatment‑naive or had failed topical agents; when seeking coverage for intracanalicular inserts, document prior topical therapy attempts or rationale for use in treatment‑naive patients.

Use trial evidence (e.g., DRCR) to support step‑therapy decisions

Clinical trial references include DRCR Network and other trials assessing dexamethasone as adjunct to anti‑VEGF; these trial data inform step‑therapy expectations such as requiring prior anti‑VEGF before implants in persistent DME.

Document informed consent including cataract and IOP risks

Providers should document that patients were counseled about potential adverse effects including cataract formation, increased intraocular pressure (or hypotony), endophthalmitis, and the possible need for additional surgical procedures as part of informed consent for intravitreal implants.

Include indication, prior treatments, and rationale in supporting documentation

Support PA and billing with documentation of the specific indication (e.g., chronic noninfectious posterior uveitis, DME, RVO macular edema, postoperative inflammation), prior treatments and responses, and clinical rationale for selecting an implant.

Document rationale and risks for prophylactic intravitreal dexamethasone use

Prophylactic intravitreal dexamethasone at cataract surgery in uveitis patients is supported only by a small RCT with limitations; if used, document the prophylactic rationale, prior therapies, and risk considerations (including IOP risk) in the record and PA.

Document medical necessity with policy-listed diagnosis codes

When billing, document medical necessity by linking the billed procedure to an appropriate listed diagnosis code from the policy (e.g., diabetic macular edema, retinal vein occlusion, chorioretinal inflammation) to support coverage.

Include appropriate ICD‑10‑CM diagnosis when billing J1096 (e.g., ocular pain codes)

When submitting claims for J1096, include an appropriate supporting ICD‑10‑CM diagnosis (examples in the policy include ocular pain codes such as G89.18 and H57.10–H57.13) to align diagnosis and procedure coding.

Submit claims using current policy-aligned procedure and diagnosis codes

The policy history documents that CPT/HCPCS and ICD‑10 codes have been added, removed, and updated; providers must submit claims using the codes currently aligned with the policy's coding tables to avoid administrative denials.

Expect denials for investigational indications listed in policy

Use for indications expressly labeled investigational (for example birdshot retinochoroidopathy, cystoid macular edema related to retinitis pigmentosa, idiopathic macular telangiectasia type 1, postoperative macular edema, radiation retinopathy, or Yutiq for chronic posterior uveitis) may trigger denial as investigational.

Anticipate denials or extra documentation due to cataract and IOP adverse‑event risks

High rates of cataract formation and intraocular pressure elevation are associated with many intravitreal steroid implants; lack of long‑term benefit or insufficient evidence in some indications (e.g., certain DME uses, AMD combinations) may lead to coverage denial or require detailed documentation of prior therapies and risk–benefit considerations.

Code listing alone does not guarantee coverage—verify member benefits

Identification of a code in the coding section does not guarantee coverage; coverage is determined by the member’s benefit information and medical necessity determinations—verify benefit eligibility.

Risk of denial if service does not meet 'medically necessary' criteria

Services not meeting the policy's 'Covered when medically necessary' criteria (e.g., procedures billed under J7313/J7312 without meeting medical necessity) may be denied; ensure submitted clinical information meets the policy criteria.

Avoid coding mismatch between procedure and supporting diagnosis

Claims may be denied if the procedure/diagnosis coding is mismatched—for example, billing codes other than J1096 when associated with the ocular pain diagnosis codes listed, or using a procedure code not aligned with the policy's diagnosis table.

Check policy history and coding updates to prevent administrative denials

Administrative or coding misalignment—such as using codes that were removed or reclassified in policy history—can trigger claim denials; verify current policy coding and administrative updates before submission.

Refer to Background for clinical context and definitions

See Background section for clinical context on uveitis, macular edema, and implant types (intravitreal vs nonbiodegradable versus biodegradable) if additional clinical rationale or definitions are needed for PA documentation.